Cipher Pharmaceuticals Inc.

TSX:CPH.TO

Drug Manufacturers - Specialty & Generic

Healthcare
$13.05 +0.94%

+$0.15 today

Market cap
$331.67M
Beta
0.48
P/E (TTM)
9.3
EPS (TTM)
$1.22
52W Low $11.98High $20.56

Volume 0.04M

Average 0.03M

CPH.TO EBITDA

Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.

Cipher Pharmaceuticals Inc.TSX: CPH.TO

EBITDA · Q1 FY2026 · quarter ended Mar 2026

EBITDA grows, but more slowly than its trailing trend

Q1 FY2026 EBITDA of $7.28M rose 69.5% year over year, behind the +96.0% change in trailing-twelve-month EBITDA. Sequentially, it rose 70.6% from the prior quarter. Over 3 fiscal years it compounded at +26.0% a year.

Context

  • EBITDA amounted to 46.9% of revenue in FY2025, up 11.4 pp from a year earlier.
  • EBITDA increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether EBITDA reaches the consensus estimate from 4 analysts of $33.01M (+37.0%) for the fiscal year ending Dec 2026, a slowdown from the +103.1% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
$7.28M+70.6% QoQ
Last fiscal yearDec 2025
$24.1M+103.1% YoY
LTMMar 2026
$25.12M+96.0% YoY
EBITDA past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+69.5%+9.3%-60.2 pp
1 year+103.1%+37.0%-66.1 pp
3-year CAGR+26.0%+1.9%-24.2 pp
5-year CAGR+2.9%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA history

USD · from the income statement

Latest · FY2025
24.1M USD
Year-over-year change
+103.1%
4-year CAGR
+15.2%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA vs competitors

How CPH.TO compares with its peers on the latest reported figures

  • Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +96.0% is the 2nd highest of 8, against a peer median of -6.0%.
  • EBITDA amounts to 49.3% of revenue for CPH.TO, versus a peer median of 14.9%.
CPH.TO Competitors
EBITDA for CPH.TO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
GUD.TOKnight Therapeutics Inc.LTM Mar 2026CA$65.18M CAD-6.0%+29.1%12.8%
TSND.TOTerrAscend Corp.LTM Mar 2026$60.46M USD+510.4%—23.1%
CPH.TOCipher Pharmaceuticals Inc.LTM Mar 2026$25.12M USD+96.0%+26.0%49.3%
ACB.TOAurora Cannabis Inc.LTM Mar 2026CA$9.82M CAD-80.9%—3.1%
FRX.TOFennec Pharmaceuticals Inc.LTM Mar 2026-$5.36M USD+48.2%—10.5%
EDT.TOSpectral Medical Inc.LTM Mar 2026-CA$35.21M CAD-81.6%—1275.3%
OGI.TOOrganiGram Holdings Inc.LTM Mar 2026-CA$40.84M CAD-681.4%—14.9%
WEED.TOCanopy Growth CorporationLTM Mar 2026-CA$63.48M CAD+86.8%—20.4%
Peer median (excluding CPH.TO) —-6.0%+29.1%14.9%

Competitors are the stored peer set for CPH.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue21.94M20.68M21.16M33.36M51.33M
Cost of Revenue3.68M3.99M4.07M9.26M17.56M
Gross Profit18.26M16.68M17.09M24.1M33.77M
Gross Margin83.2%80.7%80.8%72.2%65.8%
Research & Development88K98K139K021.37K
Selling, General & Admin5.11M4.4M5.43M12.24M16.3M
Operating Expenses6.45M5.63M5.56M16.26M16.97M
Depreciation & Amortization701K989K1.23M4.02M7.23M
EBITDA13.66M12.04M11.53M11.87M24.1M
EBITDA Margin62.2%58.2%54.5%35.6%46.9%
Operating Income11.82M12.04M11.53M7.85M16.8M
Operating Margin53.9%58.2%54.5%23.5%32.7%
Interest Income12K464K1.87M330K0
Interest Expense92K0001.19M
Other Income / Expenses(2M)(560K)1.15M(4.89M)661.38K
Income Before Tax11.06M11.48M12.68M2.96M17.46M
Pre-Tax Margin50.4%55.5%59.9%8.9%34.0%
Income Tax Expense3.3M(15.16M)(7.7M)(8.59M)(10.34M)
Net Income7.76M26.64M20.38M11.55M27.81M
Net Margin35.4%128.8%96.3%34.6%54.2%
EPS (Basic)0.291.060.800.471.09
EPS (Diluted)0.291.040.800.471.07
Weighted Avg Shares26.6M25.13M25.48M24.72M25.48M
Weighted Avg Shares (Diluted)26.83M25.59M25.42M24.57M25.99M

Cipher Pharmaceuticals Inc.

TSX:CPH.TO

Intrinsic Alpha fair value

Locked

Current Price

$13.05

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.